Dr Kurt Miller from Berlin, Germany, argues against chemotherapy remaining as the standard treatment for symptomatic mCRPC in the era of novel agents.
He shows the strong evidence supporting agents in the pre-chemotherapy space, such as abiraterone and enzalutamide.
He also shows the evidence supporting sipuleucel-T and alpharadin. Dr Miller notes that chemotherapy will still have a role in mCRPC, but probably second-, third- or fourth-line.